News & Updates

Is it safe to use pyrazinamide in older patients with TB?
Is it safe to use pyrazinamide in older patients with TB?
01 Oct 2024 byStephen Padilla

Adding pyrazinamide (PZA) to the initial tuberculosis (TB) treatment in older patients may lead to an increase in the incidence of adverse events (AEs), particularly allergic reactions, but not in-hospital mortality, length of hospital stay, or hepatotoxicity, reports a study, which used data from the Japanese Diagnosis Procedure Combination inpatient database.

Is it safe to use pyrazinamide in older patients with TB?
01 Oct 2024
Autism risk in children not heightened by COVID-19 pandemic exposure
Autism risk in children not heightened by COVID-19 pandemic exposure
29 Sep 2024 byJairia Dela Cruz

Children born during the COVID-19 pandemic or to mothers with history of prenatal SARS-CoV-2 infection are not at increased risk of autism compared with their counterparts who were born before the pandemic or have no exposure to maternal SARS-CoV-2 infection, as reported in a cohort study.

Autism risk in children not heightened by COVID-19 pandemic exposure
29 Sep 2024
Long-term bulevirtide use safe, efficacious in chronic HDV
Long-term bulevirtide use safe, efficacious in chronic HDV
29 Sep 2024 byStephen Padilla

Longer treatment with bulevirtide (BLV) monotherapy in patients with chronic hepatitis delta (CHD) for 96 weeks results in sustained or continued improvements in virologic, biochemical, and combined responses, a study has shown.

Long-term bulevirtide use safe, efficacious in chronic HDV
29 Sep 2024
Large UK study underpins role of COVID-19 vax in mental illness
Large UK study underpins role of COVID-19 vax in mental illness
27 Sep 2024
Acute kidney injury: An under-recognized complication of seasonal flu
Acute kidney injury: An under-recognized complication of seasonal flu
25 Sep 2024
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024 byJairia Dela Cruz

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024